March 13, 2012 -- Boehringer Ingelheim will invest $15.7 million to build an Asian R&D center located in Shanghai’s Zhangjiang HiTech Park. The center, the first animal health center in China for BI, will be devoted to developing vaccines for diseases that are prevalent among China’s livestock. It will contain space for 70 workstations. BI positioned the investment as part of the company’s larger initiative to increase veterinary revenues in China. More details....
